Vita Golubovskaya

Vita Golubovskaya

ProMab Biotechnologies. Inc

Affiliated withProMab Biotechnologies. IncProMab Biotechnologies

Research Area

Biography

Dr. Vita Golubovskaya is a Director of Research and Business Development at Promab Biotechnologies leading research of novel anti-cancer immunotherapies including CAR-T cell therapy. She has more than 20 years of experience in cancer research, oncology and immunology. Previously, Dr. Golubovskaya was a Research Associate Professor at Roswell Park Cancer Institute and Research Professor at University of Buffalo, SUNY, Buffalo, NY. She holds Ph.D in Cell Biology from Institute of Cytology, St. Petersburg, Russia. Dr. Golubovskaya authored more than 80 publications, 20 patents and several book chapters. She was awarded Susan Komen Grant for Breast Cancer, NCI NIH and STTR grants. Dr. Golubovskaya served as a Guest Editor in Frontiers in Bioscience, Anti-Cancer Agents in Medicinal Chemistry and Cancers. She is an Active Member of AACR.

JoVE Journal Publications

ArticleTotal : 2
Year
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Publication title

Cited by 10

2019
2025

Other Publications

Article
Year
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.

Cancers| PubMed ID: 26999211

2016
FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells and .

Frontiers in bioscience (Landmark edition)| PubMed ID: 28410137

2017
2017
2017
GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.

Frontiers in bioscience (Landmark edition)| PubMed ID: 29772559

2018
2018
Generation of CAR-T Cells for Cancer Immunotherapy.

Methods in molecular biology (Clifton, N.J.)| PubMed ID: 30465215

2019
2019
Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells and .

Frontiers in bioscience (Landmark edition)| PubMed ID: 31585889

2020
Major Highlights of the CAR-TCR Summit, Boston, 2016.

Anti-cancer agents in medicinal chemistry| PubMed ID: 28071584

2017
2019
PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells.

Frontiers in bioscience (Landmark edition)| PubMed ID: 32472757

2020
2020
2021
2021
2021
CAR-T Cells Targeting Immune Checkpoint Pathway Players.

Frontiers in bioscience (Landmark edition)| PubMed ID: 35468680

2022
2022
2022
Cancer Immunotherapy: Where Next?

Cancers| PubMed ID: 37190286

2023
2023
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.

International journal of molecular sciences| PubMed ID: 37686170

2023
2023
2024